TRANSLATIONAL MEDICINE 2017 is the third bi-annual conference organised by EATRIS. This event, open to a wide range of stakeholders (pharma industry, academia, research funders), will bring together experts and key actors in translational research, to discuss current approaches and future perspectives in the ﬁeld.
The theme of this third edition will be “Enhancing Predictivity in Medicines Development” and will focus on bringing together the latest approaches to increase chances of success in drug development, from novel in vitro systems to new biomarkers or clinical trial methodology for patient selection and stratification.
THE PROGRAMME IN A NUTSHELL
The conference will start on Sunday, September 24 with a series of educational workshops. The workshops will be dedicated to key topics in the ﬁeld such as molecular imaging, biomarker validation or potency assays for ATMP’s and vaccines. Read more about our educational workshops. Please note that space is limited to 25 persons per workshop and registration is on first-come, first-serve basis.
For the main conference on September 25 and 26, the event will be structured around 3 plenary sessions, introduced by keynote speakers:
Session 1: The Funder, Developer and Regulator as Partners in Innovation
Session 2: Novel approaches in clinical development
Session 3: Developing more predictive preclinical tools to better reach proof of concept
For this year’s edition, we will hear from – among others – Mark Schmidt (Senior Director, Janssen Research and Development), Philip Murphy (Head, Experimental Medicine Imaging, GSK), Christopher Austin (NIH-NCATS, United States). Find out all about our keynote speakers.
Following its inaugural conference in 2013, EATRIS organised its second conference in May 2015 in Amsterdam, named “Building Bridges in Translational Medicine”. The event gathered 250 European and international stakeholders to discuss how we can better meet the challenges facing drug and diagnostic development.
Our 2015 high level keynote speakers included Prof. Nicole Deglon (Lausanne University Hospital, Switzerland), Prof. Kate Bushby (Newcastle University, United Kingdom), Prof. Mats Bergstrom (imaging-enabled drug development expert, Sweden).
POWERED BY EATRIS
EATRIS ERIC, the European Infrastructure for Translational Medicine, specialises in advancing medicines safely and eﬀectively into clinical development. With over 80 leading academic translational research institutions across Europe, it provides cutting edge infrastructure and expertise along the entire translational value chain.
EATRIS is a ’One-stop-shop’ that gives you access to pre-clinical validation, manufacturing, non-clinical and clinical development capabilities of 80+ academic institutions.